P/E của cổ phiếu GRFS là bao nhiêu?

GRIFOLS SA ADR (GRFS) hiện giao dịch ở mức P/E 12.33 lần.

ROE của cổ phiếu GRFS là bao nhiêu?

GRIFOLS SA ADR có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 8.16%.

Tỷ suất cổ tức của GRFS là bao nhiêu?

GRIFOLS SA ADR có tỷ suất cổ tức 3.43%.

Điểm chất lượng (Quality Score) của GRFS là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của GRFS ở mức 62/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu GRFS không?

Điểm AI Timing của GRFS là 63/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu GRFS thuộc ngành nào?

GRIFOLS SA ADR được xếp vào ngành Healthcare >> Drug Manufacturers - General trên sàn NASDAQ

Cổ phiếu GRFS (NASDAQ) | GRIFOLS SA ADR

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-06-30)

GRFS AI Analysis Summary

Our AI summary for GRFS: GRIFOLS SA ADR (NASDAQ), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 12.33, ROE of 8.16%, a dividend yield of 3.43%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 63/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

GRFS

GRIFOLS SA ADR

USD 7.87

-0.33 (-4.02%) Day Change

Watchlist Portfolio Compare Chart

12.33

P/E

1.29

D/E

8.2%

ROE

2.3%

ROA

3.43%

Div Yield

0.11

PEG

GRIFOLS SA ADR
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 7.87 Price -0.33 (-4.02%) Day Change	NEWS SCORE: 74

GRFS Chất lượng tổng thể của cố phiếu Khá ( Chất lượng = 62) và Thời điểm mua ...(Sign In to See)...

Loading chart...

62 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: Tỷ lệ ROE tương đối thấp
Lịch sử ROE tương đối thấp
ROA quá thấp so với ROE
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt lắm , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...

Yếu tố Chất lượng

57%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	74
Magic Formula Rank by ROA	1665
Magic Formula Rank by ROE	1665
Magic Formula Rank by ROIC	1289
Price	7.87
PBV / Sector	0.70 / 2.68 GREAT
Earning Per Share	0.64

PE / Sector	12.33 / 27.65 GOOD
PEG or PE/Growth / Sector	0.11 / 0.28 GREAT
Average 1M Daily Value	5.27 M GREAT
Average 1W Daily Value	8.31 M

Yếu tố Kỹ thuật

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

39%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

62%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	6.09 / 17.30
NPM Average (%) / Sector	3.46 / 17.60
NPM Change Average (%) / Sector	79.88 / 92.67 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	2.25 / 8.73
ROA Average (%) / Sector	1.20 / 8.56
ROA Change Average (%) / Sector	92.17 / 94.23 GREAT
ROE (%) / Sector	8.16 / 26.78
ROE Average (%) / Sector	4.44 / 13.05
ROE Change Average (%) / Sector	87.13 / 96.64 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

62%

Dividend (%) / Sector	3.43 / 2.40 GOOD
Dividend Average (%) / Sector	2.64 / 3.39
Dividend Change Average (%) / Sector	85.38 / 4.92 GREAT

Chi tiết đăng ký

Analyze Date	2026-08-01 07:59:55
Symbol	GRFS
Name	GRIFOLS SA ADR
Sector	Healthcare >> Drug Manufacturers - General
Market	NASDAQ
Listed Shares	258.22 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	5,580.76 / 256,404.20

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Parque Empresarial Can Sant Joan, Barcelona, Spain, 08174

Phone: 34 935 71 22 00

Website: https://www.grifols.com

Employees: 25,000

Sector: Healthcare >> Drug Manufacturers - General

Description: Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.